The increased demand for plasma-derived factor VIII in Italy between 2011 and 2014 is attributable to treatment of adult patients rather than paediatric or previously unexposed patients with severe haemophilia A

Blood Transfus. 2017 May;15(3):281-282. doi: 10.2450/2017.0285-16. Epub 2017 Mar 2.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adult
  • Child
  • Factor VIII*
  • Hemophilia A*
  • Humans
  • Italy
  • Plasma

Substances

  • Factor VIII